NASDAQ:MYOK - MyoKardia Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $207.40
  • Forecasted Upside: -7.79 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 10 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$224.91
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New MyoKardia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$207.40
▼ -7.79% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for MyoKardia in the last 3 months. The average price target is $207.40, with a high forecast of $225.00 and a low forecast of $86.00. The average price target represents a -7.79% upside from the last price of $224.91.
Hold
The current consensus among 11 polled investment analysts is to hold stock in MyoKardia. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/3/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
3/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
5/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 0 sell ratings
8/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 11 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings
11/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/15/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
i
Rating by A. Young at Cantor Fitzgerald
10/6/2020CSFBReiterated RatingOutperform ➝ Neutral$225.00Low
i
10/6/2020CowenDowngradeOutperform ➝ Market Perform$145.00 ➝ $225.00Low
i
10/6/2020WedbushDowngradeOutperform ➝ Neutral$127.00 ➝ $225.00Low
i
Rating by D. Nierengarten at Wedbush
10/6/2020Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$225.00Low
i
10/6/2020Wells Fargo & CompanyInitiated CoverageOverweight ➝ Equal Weight$133.00 ➝ $225.00Low
i
10/6/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$121.00 ➝ $225.00Low
i
10/6/2020CitigroupDowngradeBuy ➝ Neutral$125.00 ➝ $225.00Low
i
10/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$148.00 ➝ $225.00Low
i
10/5/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
i
10/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
10/5/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightLow
i
8/31/2020BMO Capital MarketsReiterated RatingBuy$148.00High
i
Rating by George Farmer at BMO Capital Markets
8/5/2020Credit Suisse GroupReiterated RatingBuy$136.00Low
i
7/15/2020Morgan StanleyBoost Price TargetOverweight$117.00 ➝ $121.00Medium
i
5/20/2020Cantor FitzgeraldBoost Price TargetOverweight$95.00 ➝ $188.00Medium
i
Rating by Alethia Young at Cantor Fitzgerald
5/14/2020BMO Capital MarketsBoost Price TargetOutperform$90.00 ➝ $148.00High
i
Rating by George Farmer at BMO Capital Markets
5/12/2020CitigroupBoost Price TargetBuy$87.00 ➝ $125.00Medium
i
5/12/2020WedbushBoost Price Target$90.00 ➝ $127.00High
i
5/11/2020CowenBoost Price TargetOutperform$104.00 ➝ $145.00High
i
5/11/2020Credit Suisse GroupBoost Price TargetOutperform$82.00 ➝ $136.00High
i
5/7/2020Morgan StanleyBoost Price TargetOverweight$83.00 ➝ $87.00Medium
i
4/15/2020Morgan StanleyBoost Price TargetOverweight$76.00 ➝ $83.00Medium
i
3/31/2020Cantor FitzgeraldReiterated RatingBuy$95.00High
i
Rating by Alethia Young at Cantor Fitzgerald
3/26/2020BMO Capital MarketsReiterated RatingBuy$90.00Low
i
Rating by George Farmer at BMO Capital Markets
3/5/2020CowenReiterated RatingBuy$104.00Low
i
2/28/2020Morgan StanleyBoost Price TargetOverweight$75.00 ➝ $76.00High
i
2/11/2020Credit Suisse GroupBoost Price TargetOutperform ➝ Positive$77.00 ➝ $82.00High
i
2/7/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Anupam Rama at JPMorgan Chase & Co.
1/27/2020GuggenheimReiterated RatingBuy$86.00Low
i
Rating by Etzer Darout at Guggenheim
1/17/2020Wells Fargo & CompanyBoost Price TargetOverweight ➝ Positive$82.00 ➝ $96.00Medium
i
12/20/2019CitigroupBoost Price TargetBuy$70.00 ➝ $87.00Medium
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$70.00 ➝ $75.00Low
i
Rating by Jeffrey Hung at Morgan Stanley
11/11/2019CowenReiterated RatingBuy$73.00Low
i
Rating by Ritu Baral at Cowen Inc
10/28/2019Maxim GroupReiterated RatingAverageHigh
i
10/22/2019CowenReiterated RatingBuy$73.00Low
i
Rating by Ritu Baral at Cowen Inc
9/19/2019GuggenheimInitiated CoverageBuyHigh
i
8/8/2019WedbushBoost Price TargetOutperform$87.00 ➝ $90.00Low
i
8/8/2019CowenReiterated RatingBuy$73.00High
i
7/15/2019Morgan StanleySet Price TargetBuy$71.00High
i
Rating by Jeffrey Hung at Morgan Stanley
5/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $85.00Medium
i
5/9/2019Cantor FitzgeraldReiterated RatingBuy$90.00Medium
i
3/5/2019BMO Capital MarketsBoost Price TargetOutperform$90.00Medium
i
3/4/2019Cantor FitzgeraldReiterated RatingBuy$90.00High
i
Rating by A. Young at Cantor Fitzgerald
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$85.00Low
i
1/4/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$73.00 ➝ $71.00High
i
1/3/2019CitigroupLower Price TargetBuy ➝ Buy$90.00 ➝ $70.00Medium
i
11/9/2018WedbushReiterated RatingOutperform$77.00High
i
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$90.00High
i
Rating by A. Young at Cantor Fitzgerald
9/28/2018CitigroupInitiated CoverageBuy ➝ Buy$90.00Medium
i
9/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$72.00High
i
8/10/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $81.00Medium
i
8/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $73.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
8/9/2018WedbushReiterated RatingOutperform ➝ Outperform$77.00 ➝ $64.00Medium
i
7/10/2018Bank of AmericaInitiated CoverageBuy$71.00High
i
5/22/2018CowenReiterated RatingBuy$73.00High
i
4/13/2018Wells Fargo & CompanyReiterated RatingOutperform$70.00Medium
i
3/9/2018CowenReiterated RatingBuy$56.00Low
i
3/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $83.00High
i
3/9/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $68.00High
i
3/9/2018WedbushBoost Price TargetOutperform$51.00 ➝ $69.00High
i
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$60.00Low
i
12/12/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$54.00Medium
i
9/20/2017WedbushReiterated RatingOutperform$51.00High
i
9/19/2017Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$45.00 ➝ $55.00High
i
8/21/2017BMO Capital MarketsReiterated RatingOutperform$45.00 ➝ $65.00High
i
8/8/2017BMO Capital MarketsReiterated RatingBuy$32.00 ➝ $45.00Medium
i
8/7/2017CowenBoost Price TargetOutperform$28.00 ➝ $56.00High
i
8/7/2017Wells Fargo & CompanyReiterated RatingOutperform$31.00 ➝ $48.00High
i
5/10/2017BMO Capital MarketsReiterated RatingOutperform$32.00Low
i
3/13/2017WedbushReiterated RatingOutperform$24.00High
i
11/8/2016CowenReiterated RatingBuy$28.00N/A
i
Rating by Ritu Baral at Cowen Inc
11/7/2016WedbushReiterated RatingOutperform$24.00N/A
i
9/28/2016WedbushReiterated RatingOutperform$24.00 ➝ $22.00N/A
i
9/22/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
8/9/2016WedbushReiterated RatingOutperform$22.00N/A
i
7/20/2016BMO Capital MarketsInitiated CoverageOutperform$3.00 ➝ $28.00N/A
i
7/12/2016Credit Suisse GroupReiterated RatingBuy$16.00 ➝ $20.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
5/13/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
5/12/2016WedbushReiterated RatingOutperform$22.00N/A
i
3/21/2016CowenReiterated RatingOutperform$24.00N/A
i
Rating by Ritu Baral at Cowen Inc
3/18/2016WedbushReiterated RatingOutperform$22.00N/A
i
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
(Data available from 11/26/2015 forward)
MyoKardia logo
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $224.91
$224.91
$224.91

50 Day Range

MA: $223.40
$220.67
$224.91

52 Week Range

Now: $224.91
$42.65
$225.00

Volume

N/A

Average Volume

752,969 shs

Market Capitalization

$11.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84